Glenmark enrols first patient for phase II trial of GBR 500
The company out licensed Vatelizumab (GBR 500) to Sanofi for all indications in 2011
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Research
US FDA votes against Novartis’ LBH589 compound
(ODAC) did not recommend the investigational compound LBH589, a pan-deacetylase inhibitor, for patients with previously treated…
Study confirms positive safety profile and effectiveness of Pradaxa in atrial fibrillation patients
The FDA Medicare analysis is based on patient data from elderly patients enrolled in Medicare
Psoriasis or rheumatoid arthritis linked to heart risk
Patients with psoriatic arthritis were 36 per cent more likely than the comparison group to suffer a heart attack
DRDO scientists develop Ayurveda-based drug for leucoderma
DIBER has transferred the technology of the drug, which is being showcased at the ongoing Arogya Expo 2014
Shantha’s investigational rotavirus vaccine enters phase III clinical trials in India
The live, oral, ready-to-use tetravalent rotavirus vaccine candidate is designed to protect young children from severe diarrhoea
Promethera Biosciences receives approval in Belgium
To enroll patients in the imminent HEP002 Phase IIb/ III clinical trial
US FDA approves first combination pill to treat hepatitis C
Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection
Akynzeo gets US FDA approval
Akynzeo treats nausea and vomiting in patients undergoing cancer chemotherapy
Novartis’ Gilenya reduces brain shrinkage matters for people with MS
Patients who had the highest rates of brain shrinkage at two years had a higher risk of disability progression at four years